Why is "Cholangiocarcinoma" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-29 03:11:34
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Cholangiocarcinoma entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-03-29 and was most recently seen on 2026-03-29.
Wikipedia Overview
Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts. Symptoms of cholangiocarcinoma may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever. Light colored stool or dark urine may also occur. Other biliary tract cancers include gallbladder cancer and cancer of the ampulla of Vater.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
HLB's Cholangiocarcinoma Drug Seeks European Approval as U.S. Review Deadline Looms on the 25th - finance.biggo.com
-
FDA Approves Zenocutuzumab for Cholangiocarcinoma Based on MSK-Led Trial - Memorial Sloan Kettering Cancer Center
-
Cholangiocarcinoma:Unveiling the cold tumor microenvironment and strategies for immune rejuvenation - Nature
-
Ablative Radiotherapy May Improve Outcomes for Patients With ‘Supermassive’ Intrahepatic Cholangiocarcinoma - The ASCO Post
-
Sequencing of Fibroblast Growth Factor Receptor Inhibitors in Cholangiocarcinoma: A Review of Published Cases - ASCO Publications
-
China's NMPA Approves Fanregratinib for Pretreated FGFR2+ Intrahepatic Cholangiocarcinoma - OncLive
-
Case Report: Response to ivosidenib in patients with cholangiocarcinoma: a clinical perspective with illustrative cases - Frontiers
-
Elevar Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Lirafugratinib as a Treatment for Patients with Advanced/Metastatic Cholangiocarcinoma (CCA) Harboring FGFR2 Fusions or Rearrangements - The Manila Times
-
RAS -ing the bar in the treatment of KRAS -mutant cholangiocarcinoma - ScienceDirect.com
-
Dr. Sita Kugel Investigates the Biology of Pancreatic Cancer and Cholangiocarcinoma - National Cancer Institute (.gov)
-
First-Line Pemigatinib Improves Some Outcomes in Metastatic Cholangiocarcinoma - Cancer Therapy Advisor
-
Cholangiocarcinoma Drugs Market Size, Share | Growth [2034] - Fortune Business Insights
-
Changing concepts in perihilar cholangiocarcinoma resections and surgery - Ovid
-
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy - CancerNetwork
-
Comparative analysis of genomic profiles and clinical outcomes in cholangiocarcinoma and gallbladder cancer - Nature
-
Zenocutuzumab Shows Durable Antitumor Activity in NRG1 -Positive Cholangiocarcinoma - The ASCO Post
-
Case Report: Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma - Frontiers
-
First-Line Pemigatinib Drives PFS Benefit in FGFR2-Rearranged Cholangiocarcinoma - OncLive
-
High-resolution spatial multi-omics enables prognostic scoring in intrahepatic cholangiocarcinoma - ScienceDirect.com
-
Proteomic characterization of intrahepatic cholangiocarcinoma identifies risk-stratifying subgroups and EIF4A1 as a therapeutic target - Nature
-
FDA Approves Bizengri for Advanced, Unresectable or Metastatic Cholangiocarcinoma - Cure Today
-
Mayo Clinic researchers use milk-derived nanoparticles to target aggressive bile duct cancer - Mayo Clinic News Network
-
FDA Grants Priority Review to Lirafugratinib in FGFR2+ Cholangiocarcinoma - CancerNetwork
-
Zenocutuzumab sBLA Filed With FDA for NRG1-Positive Cholangiocarcinoma - Targeted Oncology
-
FDA Approves Zenocutuzumab for NRG1 Fusion–Positive Cholangiocarcinoma - Targeted Oncology
-
Harnessing cellular immunotherapy for cholangiocarcinoma: an integrated roadmap for overcoming resistance - Frontiers
-
Profiling ADC targets in cholangiocarcinoma: implications for therapeutic development - Nature
-
Could milk-derived nanoparticles change bile duct cancer care? - Mayo Clinic News Network
-
New Genetic ‘Roadmap’ Advances Precision Therapy for Intrahepatic cholangiocarcinoma | Cell Reports Medicine - bgi.com
-
FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma - OncLive
-
Salvage resection for FGFR2 fusion-positive intrahepatic cholangiocarcinoma after pemigatinib therapy: a case report and literature review - Frontiers
-
FDA Approves OncoSil Device for Unresectable Distal Cholangiocarcinoma - Oncology Nursing News
-
Remembering Sydney Towle: How a Young Influencer Turned a Rare Cancer Diagnosis Into a Global Conversation - Oncodaily
-
Interpretable multimodal deep learning improves postoperative risk stratification in intrahepatic cholangiocarcinoma in multicentre cohorts - Nature
-
Partner Therapeutics Announces Publication of Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma in Journal of Clinical Oncology (JCO) - PR Newswire
-
Partner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner's National Priority Voucher - PR Newswire
-
Intrahepatic Cholangiocarcinoma: The Weight of History - Cureus
-
FDA Approval Is Sought for Zenocutuzumab in NRG1+ Cholangiocarcinoma - OncLive
-
Wife of cholangiocarcinoma patient makes gift in honor of husband - news.vumc.org
-
HLB Submits European Marketing Authorization Application for New Cholangiocarcinoma Drug - 아시아경제
-
Neoadjuvant therapy regimen improves outcomes in high-risk intrahepatic cholangiocarcinoma - 2 Minute Medicine
-
Lirafugratinib Produces Durable Responses in FGFR2 Fusion Cholangiocarcinoma Trial - Oncology News Central
-
FDA Receives sBLA for Zenocutuzumab in Advanced NRG1+ Cholangiocarcinoma - CancerNetwork
-
Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial - Nature
-
Exosomes and cholangiocarcinoma: mechanisms, diagnostic, and therapeutic perspectives - Frontiers
-
Prognostic value of preoperative serum ferritin in cholangiocarcinoma patients - Nature
-
Amino acid metabolic reprogramming: future prospects for cholangiocarcinoma therapy - Nature
-
Zenocutuzumab for NRG1-Positive Cholangiocarcinoma - HMP Global Learning Network
-
Radiation therapy improves outcomes for 'supermassive’ bile duct tumors - UT MD Anderson
-
A case of synchronous double primary combined hepatocellular-cholangiocarcinoma complicated with gallbladder adenocarcinoma: a rare case report - Frontiers
-
Cholangiocarcinoma derived exosomes attenuate the anti-tumor functions of NK cells | Scientific Reports - Nature
-
Long-term complete remission of metastatic combined hepatocellular-cholangiocarcinoma with nivolumab following failure of targeted therapies: a case report - Frontiers
-
Intraductal Papillary Neoplasm With Associated Invasive Cholangiocarcinoma and Biliary Intraepithelial Neoplasia in Primary Sclerosing Cholangitis: A Case Report - Cureus
-
Zenocutuzumab‑zbco Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma - PR Newswire
-
City of Springfield and Jeffrey Speller Foundation join in recognizing Cholangiocarcinoma Awareness Month - Springfield-MA.gov
-
Circulating Tumor DNA in Cholangiocarcinoma: A Precision Oncology Roadmap - Dove Medical Press
-
Microbial dysbiosis in cholangiocarcinoma - Frontiers
-
Pemigatinib for unresectable advanced or metastatic cholangiocarcinoma with FGFR2 rearrangement: results from the confirmatory Phase 3 FIGHT-302 trial - OncLive
-
Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma - CancerNetwork
-
FDA Approves Zenocutuzumab for NRG1 Fusion-Positive Cholangiocarcinoma - biopharminternational.com
-
Bizengri Approved for Advanced NRG1 Fusion-Positive Cholangiocarcinoma - Oncology Nurse Advisor
-
February: Cholangiocarcinoma Awareness Month - Hospital Clínic Barcelona
-
FDA Grants Orphan Drug Designation to Zenocutuzumab in Cholangiocarcinoma - CancerNetwork
-
The ESMO Advanced Course on Cholangiocarcinoma 2026 - Oncodaily
-
Partner Therapeutics announces submission of supplemental Biologics License Application (sBLA) to FDA for BIZENGRI® (zenocutuzumab-zbco) in NRG1 Fusion Positive Cholangiocarcinoma and Inclusion in updated NCCN Clinical Practice Guidelines in O - PR Newswire
-
Eosinophilic cholangitis misdiagnosed as cholangiocarcinoma: a case report - Frontiers
-
Dr Bekaii-Saab on the FDA Approval of Zenocutuzumab in NRG1+ Cholangiocarcinoma - OncLive
-
Sydney Towle, social media content creator, dies in Maryland at 26 after documenting life with rare cancer - CBS News
-
A deceptively benign biliary lesion revealing an ALK‐rearranged intrahepatic cholangiocarcinoma - Wiley Online Library
-
Cholangiocarcinoma in a central bearded dragon ( Pogona vitticeps ): A case report - Wiley Online Library
-
New genetic ‘roadmap’ advances precision therapy for intrahepatic cholangiocarcinoma - EurekAlert!
-
FDA Grants Orphan Drug Designation to Zenocutuzumab for Cholangiocarcinoma - Cure Today
-
Cholangiocarcinoma: U.S. incidence and prevalence continue to climb, with persistent racial disparities - Vera Health
-
Targeting m6A Reader YTHDF1 Enhances Antitumor Immunity and Potentiates Anti‐PD‐L1 Efficacy in Intrahepatic Cholangiocarcinoma - Wiley & Sons
-
Cholangiocarcinoma Foundation Advances Patient Support With CholangioPath - Oncodaily
-
Lirafugratinib Seeks FDA Approval in Second Line for FGFR2-Altered Cholangiocarcinoma - OncLive
-
HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma - Yahoo Finance
-
Lirafugratinib NDA Seeks FDA Approval in Cholangiocarcinoma - Targeted Oncology
-
Mirizzi Syndrome Mimicking Cholangiocarcinoma Complicated by Infected Biloma Formation Following Complex Biliary Intervention: A Case Report - Cureus
-
Cholangiocarcinoma: Is Preoperative Histologic Confirmation Mandatory Before Major Hepatobiliary Surgery? - Cureus
-
Clinical Trials at CU Anschutz Cancer Center Offer New Hope to Bile Duct Cancer Patients - University of Colorado Anschutz
-
ASO Editorial: Preoperative Systemic Therapy for Perihilar Cholangiocarcinoma - Springer Nature Link
-
Pemigatinib Improves Outcomes Compared With Chemotherapy in FGFR2-Rearranged Cholangiocarcinoma - HMP Global Learning Network
-
TERT genetic variant may protect against cholangiocarcinoma but predict poorer survival - EurekAlert!
-
New hope for bile duct cancer - Mayo Clinic Press
-
Liver Transplantation for Intrahepatic Cholangiocarcinoma: A Nationwide Analysis of Outcomes - Stanford Medicine
-
Dr Goyal on Efficacy Data With Lirafugratinib in FGFR2-Altered Cholangiocarcinoma - OncLive
-
Metachronous cholangiocarcinoma following pancreaticoduodenectomy and the potential role of a migrated pancreaticojejunal stent: a case report and review of the literature - Frontiers
-
FIGHT-302 Data to Detail Pemigatinib's Phase 3 Showing vs Chemo in Frontline FGFR2+ CCA at ASCO 2026 - OncLive
-
Pemigatinib-Associated Psoriasis in a Patient With Cholangiocarcinoma - Cureus
-
Novel TROP2-Targeting ADC Gains FDA Orphan Drug Status in Cholangiocarcinoma - Targeted Oncology
-
MCL-1 as a tumor microenvironment-linked survival node in cholangiocarcinoma - Frontiers
-
Tertiary lymphoid structure topotypes in intrahepatic cholangiocarcinoma: spatial immunity, checkpoint-response associations, and therapeutic reprogramming - Frontiers
-
February is Cholangiocarcinoma Awareness Month - Springfield-MA.gov
-
FDA Approved Zenocutuzumab-zbco for Advanced NRG1 Fusion-Positive Cholangiocarcinoma - Oncodaily
-
LncRNA PVT1 promotes proliferation, migration and invasion of cholangiocarcinoma by regulating the expression of SOCS2 - Nature
-
Zenocutuzumab Expands Targeted Treatment Options for NRG1 Fusion-Positive Cholangiocarcinoma - HMP Global Learning Network
-
Cholangiocarcinoma: Treatment, Genomics and Supportive Care - Cure Today
-
Integrated analysis reveals survival-related genes promoting cholangiocarcinoma progression via G2/M cell cycle, with validation of cyclin B1 in tumor proliferation - Nature
-
MBNL3 regulates tumor progression and metastasis in cholangiocarcinoma and serves as a prognostic biomarker - Nature
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.